Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
出版年份 2021 全文链接
标题
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
作者
关键词
-
出版物
Cell Death & Disease
Volume 12, Issue 10, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-09-25
DOI
10.1038/s41419-021-04154-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- SynergyFinder 2.0: visual analytics of multi-drug combination synergies
- (2020) Aleksandr Ianevski et al. NUCLEIC ACIDS RESEARCH
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
- (2018) Zhaodong Li et al. LEUKEMIA
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
- (2018) Michele Massimino et al. Molecular Cancer
- T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
- (2018) Minori Tamai et al. Scientific Reports
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- MCL-1 inhibition in cancer treatment
- (2018) Weiguo Xiang et al. OncoTargets and Therapy
- Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
- (2017) Yupeng Wang et al. NATURE
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells
- (2017) H S Madapura et al. ONCOGENE
- Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death
- (2017) Corey Rogers et al. Nature Communications
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
- (2015) Jianjin Shi et al. NATURE
- Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival
- (2014) Y. Kikushige et al. JOURNAL OF IMMUNOLOGY
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Establishment And Characterization Of A Novel Philadelphia- Chromosoe Positive Chronic Myeloid Leukemia Cell Line, TCC-S, Expressing P210 And P190 BCR/ABL Transcripts But Missing Normal ABL Gene
- (2010) Phan Nguyen Thanh Van et al. Human Cell
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now